Business Daily Media

Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma

  • Written by PR Newswire
Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma


  • Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight
  • No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2
  • Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned
  • Recruitment of cohort 3 is open at all five clinical sites in the US at the increased dose level of 275MBq/kg body weight
  • Additional therapy cycles of 67Cu SARTATE™ have been requested by clinical sites and administered to participants in cohort 1 and cohort 2
  • Additional clinical sites will be opening in the US in the coming months

SYDNEY, Aug. 23, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has completed cohort 2 and advanced to cohort 3 in the theranostic 64Cu/67Cu SARTATE™ neuroblastoma trial (CL04 trial). 

The independent Safety Review Committee (SRC) assessed the safety data from cohort 2 in all three participants, confirming no Dose Limiting Toxicities (DLTs) occurred following the administration of a single therapy cycle of 67Cu-SARTATE. The SRC has recommended the trial progress to cohort 3, without modification, increasing the 67Cu SARTATE™ dose from 175MBq/kg body weight in cohort 2 to 275MBq/kg body weight in cohort 3. Additional therapy cycles of 67Cu SARTATE™ have been requested by clinical sites and are being administered to participants in cohorts 1 and 2. Subsequent therapy cycles are contingent on the Investigators assessment that the participant is demonstrating therapeutic benefit.

Clarity's Executive Chairman, Dr Alan Taylor, commented, "Our team of colleagues and collaborators are very excited to advance the SARTATE™ product in neuroblastoma, an aggressive childhood cancer. With cohort 2 of this theranostic trial now completed, we look forward to exploring the therapeutic benefits of using an increased dose of 67Cu SARTATE™ in these children, where no other options are available. The further increase in dose between cohorts 2 and 3 is significant, and we look forward to analysing the safety and efficacy data in these higher-level cohorts in neuroblastoma, a radiation sensitive disease.

"We are also pleased with the speed of recruitment in cohort 2 and have been able to close this cohort in 6 months. The increased pace of recruitment is due to the subsided effects of the global pandemic. We continue to progress the trial at some of the leading cancer centres in the US and will aim to open additional clinical sites in the US over the coming months to further accelerate the speed of recruitment in this trial.

"Improving treatment outcomes of children with cancer is at the heart of our mission and something we are very passionate about. As such, we hope that Clarity will be able to continue building upon the mounting diagnostic and therapeutic benefits of the SARTATE™ products and improve the treatment paradigm for children with this insidious disease," said Dr Taylor.

About the CL04 trial

The CL04 trial is a Phase I/IIa theranostic (diagnosis and therapy) trial in paediatric patients with high-risk neuroblastoma using 64Cu/67Cu SARTATE™ in the US (NCT04023331[1])1. It is a multi-centre, dose-escalation, open label, non-randomised clinical trial with up to 34 patients currently conducted at five clinical sites in the US, with additional US clinical sites opening for recruitment in the coming months.


SARTATE™ is a next generation, highly targeted theranostic radiopharmaceutical. It is being developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumours (NETs). Like all Clarity products, the SARTATE™ product can be used with copper-64 (64Cu) for imaging (64Cu SARTATE™) or copper-67 (67Cu) for therapy (67Cu SARTATE™).

About Neuroblastoma

Neuroblastoma most often occurs in children younger than 5 years of age and presents when the tumour grows and causes symptoms. It is the most common type of cancer to be diagnosed in the first year of life and accounts for around 15% of paediatric cancer mortality.2 High-risk neuroblastoma accounts for approximately 45% of all neuroblastoma cases. Patients with high-risk neuroblastoma have the lowest 5-year survival rates at 40%-50%.3

In 2020, the US Food and Drug Administration (FDA) awarded Clarity two Orphan Drug Designations (ODDs), one for 64Cu SARTATE™ as a diagnostic agent for the clinical management of neuroblastoma and one for 67Cu SARTATE™ as a therapy of neuroblastoma, as well as two Rare Paediatric Disease Designations (RPDDs) for these products. Should Clarity be successful in achieving marketing approval from US FDA for these two products, RPDDs may allow the Company to access a total of two tradeable Priority Review Vouchers (PRVs) which most recently traded at USD110M per voucher.4

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.[2]


  1. Identifier: NCT04839367 <>
  2. Nadja C. Colon and Dai H. Chung 2011, "Neuroblastoma", Advances in Pediatrics, <>
  3. Valeria Smith and Jennifer Foster 2018, "High Risk Neuroblastoma Treatment Review", Children, <>
  4. Fierce Biotech 14 July 2022, Marinus parts with priority review voucher, selling skip-the-line pass to Novo Nordisk for $110M, <>

For more information, please contact:

This announcement has been authorised for release by the Executive Chairman.

View original content to download multimedia:[3]

Read more

Business Reports

Why Patagonia's purpose-driven business model is unlikely to spread

Patagonia has always sought to limit its environmental harm.Budrul Chukrut/SOPA Images/LightRocket via Getty ImagesPatagonia founder Yvon Chouinard, his wife, Malinda, and their two adult children no longer own the outdoor gear an...

Why does money exist?

Cash is pretty convenient.Dilok Klaisataporn/EyeEm via Getty ImagesCurious Kids is a series for children of all ages. If you have a question you’d like an expert to answer, send it to do...

Castellum is among the first to receive NollCO2 certification

The Korsningen block project has now been completed, and Castellum is one of the first companies in the Nordics to receive a NollCO2 (ZeroCO2) certification. The Swedish Police Authority, the tenant in the project, has...

Minomic records breakthrough commercial sale in the US

Australian diagnostics company Minomic International Ltd (Minomic) is pleased to announce that their lead product, MiCheck® Prostate,1 has recorded its initial commercial sales in the US, the world’s largest healthcare mark...

Corporate Traveller and Rex Airlines partnership a game-changer for SMEs

In a move that demonstrates a strong and game-changing commitment to the Australian SME sector, Flight Centre Travel Group’s flagship SME business, Corporate Traveller, has partnered with Rex Airlines, Australia’s larges...

5 Ways to stay germ free on a plane

In pre-Covid days, no one gave much thought to their health when travelling, but nowadays, maintaining good hygiene while travelling has never been more important.  If you have ever had the misfortune of sitting on a plane and...

Web Busters - Break into local search